Are people living with HIV have a low vulnerability to omicron variant infection: results from a cross-sectional study in China

Author:

Tan Yuting,Wu Songjie,Guo Wei,Liu Jie,Ming Fangzhao,Zou Shi,Tang Weiming,Liang Ke,Yang Junjun

Abstract

Abstract Background A surge of more than 80 million Omicron variant infected cases was reported in China less than a month after the "zero COVID" strategy ended on December 7, 2022. In this circumstance, whether people living with HIV (PLWH) in China experience a similar risk is not clear. Methods A cross-sectional study was conducted in the Wuchang District of Wuhan between December 20, 2022, and January 18, 2023 through a self-administered online survey. PLWH and HIV-negative people aged ≥ 18 years old who volunteered for this survey were eligible. The prevalence of Omicron variant infection between PLWH and HIV-negative people was compared, and the factors associated with the Omicron variant infection among PLWH and HIV-negative people were further evaluated, respectively. Results In total, 890 PLWH and 1,364 HIV-negative adults from Wuchang District were enrolled. Among these participants, 690 PLWH (77.5%) and 1163 HIV-negative people (85.3%) reported SARS-CoV-2 infection. Gender, chronic disease conditions, and COVID-19 vaccination status significantly differed between the two groups. After adjusting gender, age, comorbidities, and COVID-19 vaccination status, the risk of SARS-CoV-2 infection among PLWH was significantly lower than among HIV-negative people (aOR 0.56, 95%CI 0.42–0.76). Multivariable logistic regression analysis showed that PLWH with older age and detectable HIV-viral load (HIV-VL) had decreased risk of SARS-CoV-2 infection (aOR 0.98, 95%CI 0.96–0.99; aOR 0.59, 95%CI 0.36–0.97). Compared with PLWH receiving one/two doses of COVID-19 vaccines, no significant differences in the risk of SARS-CoV-2 infection were observed among PLWH receiving three doses of inactivated vaccines and four doses of vaccines (three doses of inactivated vaccines plus one dose of inhaled recombinant adenovirus type 5 (AD5)-vectored vaccine). Among HIV-negative people, those receiving four doses of COVID-19 vaccines had a lower risk of SARS-CoV-2 infection than those receiving one/two doses (aOR 0.14, 95%CI 0.08–0.25). Conclusions Our study proves that PLWH have a lower risk of Omicron variant infection than HIV-negative people. However, even PLWH with younger age and virological suppression should strengthen the prevention against SARS-CoV-2 infection. Three doses of inactivated vaccines plus one dose of inhaled recombinant AD5-vectored COVID-19 vaccine may provide better protection for HIV-negative people.

Funder

Medical Science and Technology Innovation Platform Support Project of Zhongnan Hospital, Wuhan University

Science and Technology Innovation Cultivation Fund of Zhongnan Hospital, Wuhan University

Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University

Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Reference28 articles.

1. Xinhua. China Focus: China releases measures to optimize COVID-19 response; https://english.news.cn/20221111/d4399114a082438eaac32d08a02bf58d/c.html (2022).

2. Xinhua. China Focus: COVID-19 response further optimized with 10 new measures; https://english.news.cn/20221207/ca014c043bf24728b8dcbc0198565fdf/c.html (2022).

3. Li K, Shi J, Liu X, Ward MP, Wang Z, Liu R, et al. Early warning signals for Omicron outbreaks in China: A retrospective study. J Med Virol. 2023;95(1):e28341. https://doi.org/10.1002/jmv.28341.

4. Lin YF, Wu X, Li Y, Bian J, Li K, Jiang Y, et al. Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China[J]. J Med Virol. 2023;95(1):e28335. https://doi.org/10.1002/jmv.28335.

5. WHO. WHO Coronavirus (COVID-19) Dashboard-Overview, 2022. https://covid19.who.int/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3